Kiniksa’s shares rose 22.2% after earnings, as the company raised full-year revenue guidance to $1.045–$1.050 billion and said ARCALYST is on track to exceed $1 billion in 2026. Q3 ARCALYST revenue was $286 million, with penetration among patients with multiple recurrences reaching 23%.
- ARCALYST revenue reached $286 million in Q3; management raised full-year revenue guidance to $1.045–$1.050 billion.
- ARCALYST penetration of the annual 14,000-patient multiple-recurrence population rose to 23% by quarter-end. The company is also targeting an additional 26,000 patients annually experiencing a first recurrence.
- Management cited growing physician consideration of ARCALYST earlier in the disease course; about 50% of surveyed physicians support its use after NSAIDs and colchicine and before corticosteroids.
- KPL-387’s pivotal Phase III trial continues to enroll and dose patients, with data expected in the second half of 2027. Kiniksa is targeting a potential launch in 2028–2029.
- KPL-1161 is on track to enter a Phase I trial by year-end.
Community Discussion